551 results for "Integration Therapy"
Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice.
ACS Pharmacol Transl Sci – March 16, 2021
Summary
Mindfulness practices can significantly amplify the positive impact of psychedelic experiences. This perspective proposes that combining mindfulness before, during, and after a psychedelic session enhances therapeutic outcomes. By cultivating introspection and emotional regulation, individuals can better integrate insights, leading to sustained improvements in mental well-being. This powerful synergy holds immense promise for clinical applications.
Abstract
Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice.
Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary.
Am J Psychiatry – January 01, 2024
Summary
Remarkably, the profound healing potential of psychedelic compounds is truly unlocked through integrated therapeutic support. Evidence strongly suggests that combining psychotherapy with these experiences is not only safe but essential for achieving lasting positive mental health outcomes. A comprehensive review of current practices and clinical data demonstrates that structured psychological guidance before, during, and after psychedelic sessions is a cornerstone of effective treatment. This integrated approach maximizes therapeutic benefits, fostering significant improvements in well-being and ensuring a supportive journey for individuals seeking transformative mental health care.
Abstract
Psychotherapy in Psychedelic Treatment: Safe, Evidence-Based, and Necessary.
LSD therapy in Dutch psychiatry: changing socio-political settings and medical sets.
Med Hist – April 01, 2002
Summary
Remarkably, LSD was once a recognized therapeutic tool in Dutch psychiatry. A historical analysis reveals how its application evolved, influenced by shifting societal views and medical practices. Early applications showed promise in addressing various mental health conditions, demonstrating its potential as a treatment. This intricate interplay ultimately shaped its integration, use, and eventual decline, offering insights into the complex forces influencing psychiatric innovation.
Abstract
LSD therapy in Dutch psychiatry: changing socio-political settings and medical sets.
Design and methodology of the first open-label trial of MDMA-assisted therapy for veterans with post-traumatic stress disorder and alcohol use disorder: Considerations for a randomized controlled trial.
Contemporary clinical trials communications – October 01, 2024
Summary
Veterans battling both PTSD and alcohol use disorder may find hope in a groundbreaking therapy approach. This pioneering trial explores MDMA-assisted psychotherapy as a dual treatment, combining supervised MDMA sessions with therapeutic support. The study follows 12 veterans through comprehensive treatment, tracking brain changes and measuring improvements in both trauma symptoms and alcohol use. Early indicators suggest this innovative approach could offer relief where traditional treatments have fallen short.
Abstract
Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) commonly co-occur and are associated with more severe symptomatology than eithe...
Consciousness, Religion, and Gurus: Pitfalls of Psychedelic Medicine
CrossRef
Summary
While psychedelic therapies show promise, a crucial insight highlights the need for precision in their development. Challenges include vague definitions of "consciousness," clinicians' personal spiritual views influencing treatment, and maintaining strict ethical boundaries. Addressing these pitfalls is essential for responsibly integrating these powerful compounds into medicine, ensuring safer and more effective patient care.
Abstract
This viewpoint identifies pitfalls in the study of psychedelic compounds including those that pose challenges for the potential use of psychedelics...
Evidence versus expectancy: the development of psilocybin therapy
BJPsych Bulletin – May 29, 2023
Summary
After 25 years of development, psilocybin therapy shows promising early clinical trial evidence for treatment-resistant depression, a significant advance in Medicine. This psychedelic treatment involves the alkaloid psilocybin, psychoeducation, and psychotherapist support. A key challenge for Psychiatry and Drug Studies is that masking in trials likely fails, making it difficult to disentangle the drug's mechanism from expectancy theory in Psychology. Future efforts must measure masking and expectancy to fully understand how psilocybin influences behavior and its potential impact on mental health.
Abstract
Summary Although the development of psilocybin therapy has come as a surprise to many, modern research with the drug has been ongoing for 25 years....
Therapeutic Protocols Using Ketamine and Esketamine for Depressive Disorders: A Systematic Review.
Journal of psychoactive drugs – January 01, 2024
Summary
No Summary
Abstract
Depression is one of the most prevalent mental health disorders globally, causing severe emotional suffering, reducing life expectancy and increasi...
Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study
Psychedelic Medicine – December 23, 2025
Summary
A pioneering group psychotherapy intervention, integrating Psilocybin, offers a new approach for mental health. An FDA-approved Phase 1 to 2 clinical trial developed a unique group facilitation model for individuals with metastatic cancer experiencing anxiety and existential distress. This intervention, a 3-day retreat, employs a secular ritual based on anthropological rites of passage. Psychotherapists guide participants through preparation, psilocybin dosing, and integration. This clinical psychology model provides communal support, making it a promising step in medicine and psychiatry for cancer patients, showing empirically demonstrated safety and efficacy outcomes.
Abstract
Background: Psilocybin therapy is an emerging treatment for cancer-related anxiety, depression, and existential distress. Most clinical trials to d...
Psychedelic medicine: safety and ethical concerns.
Lancet Psychiatry – October 01, 2020
Summary
Ensuring patient well-being is paramount for psychedelic-assisted therapy, despite its promising potential. This analysis explored vital safety protocols and ethical considerations for integrating these powerful medicines into clinical practice. It examined risks like psychological distress and misuse, alongside the ethical need for informed consent and equitable access. Findings suggest that stringent oversight, comprehensive patient screening, and robust therapeutic support enable safe, ethical administration. Careful implementation can unlock significant benefits, mitigating risks, and paving the way for responsible medical use.
Abstract
Psychedelic medicine: safety and ethical concerns.
From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence‐Based Policy and Practice
Pharmacology Research & Perspectives – April 01, 2025
Summary
The effectiveness of psychedelic therapies, like MDMA for PTSD, hinges on how they're regulated. Current medicine reviews face challenges assessing drug-assisted psychotherapy, especially when demanding two successful phase 3 randomized controlled trials. Issues with blinding and internal validity arise. The critical distinction for external validity is whether these are standalone drugs or integrated with a psychotherapist. For standalone drugs, trustworthiness is low; for drug-assisted psychology therapies, trustworthiness is high. Avoiding the extrapolation fallacy is key for psychiatry and clinical psychology to prevent rejecting effective treatments.
Abstract
ABSTRACT The recent review of a new drug application for MDMA‐assisted therapy for posttraumatic stress disorder by the United States' Food and Dru...
Psychedelics and neonihilism: connectedness in a meaningless world
Frontiers in Psychology – August 09, 2023
Summary
A compelling finding suggests psychedelics, often derived from complex alkaloids, can address a modern "meaning and alienation crisis" driving rising anxiety and depression. This crisis, termed neonihilism, highlights a profound lack of social connectedness. Integrating insights from Psychology and Social psychology, a novel approach combines these substances with group therapy. This aims to foster enhanced social connectedness and cognitive shifts, moving beyond mystical experiences. This strategy offers a structured path toward alleviating meaninglessness and improving mental well-being, leveraging the unique properties of these compounds.
Abstract
The resurgence of psychedelic research explicitly targets treating mental health conditions largely through psychedelics-assisted psychotherapy. Cu...
When death is desired: A case of MAiD & the CL psychiatrist.
Palliative & supportive care – January 21, 2025
Summary
As medical aid in dying gains legal status across regions, healthcare providers face complex end-of-life care decisions. This case explores how consultation-liaison psychiatry supports patients seeking assisted dying, while integrating palliative medicine and psycho-oncology care. The findings highlight how meaning-centered therapy and hospice care can help patients make informed choices about their end-of-life journey.
Abstract
Since physician-assisted dying (PAD) has become a part of the clinical dialogue in the United States (US) and other Western countries, it has spawn...
Study protocol for “MDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study”
Frontiers in Psychiatry – October 26, 2022
Summary
New hope emerges for Major depressive disorder, a debilitating brain disorder. A clinical trial is investigating MDMA-assisted therapy as a potential new medicine. Twelve participants will undergo MDMA dosing over two sessions, integrated with psychological support. This open-label trial in psychiatry assesses safety, including potential adverse effects, and gathers initial insights into effectiveness, aiming to inform future assessments of overall clinical impression. This work contributes to the growing field of psychedelics and drug studies.
Abstract
Background Major depressive disorder (MDD) is a world-leading cause of disability. The available treatments are not effective in all patients, and ...
Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm.
Journal of psychopharmacology (Oxford, England) – January 01, 2025
Summary
Ketamine therapy delivered in a supportive, psychedelic-inspired setting shows remarkable promise for treating severe PTSD. In a groundbreaking approach, patients received ketamine infusions combined with preparation, intention-setting, and integration sessions. Using music and eye shades during treatment, 75% of participants saw significant improvement, with 61% achieving PTSD remission. This innovative blend of ketamine-assisted psychotherapy offers new hope for those struggling with treatment-resistant trauma.
Abstract
Traditional treatments for post-traumatic stress disorder (PTSD) often show limited success with high dropout. Ketamine, an N-methyl-D-aspartate an...
Neurochemical, Neurocircuitry, and Psychopathological Mechanisms of PTSD: Emerging Pharmacotherapies and Clinical Perspectives.
ACS chemical neuroscience – June 10, 2025
Summary
Brain chemistry offers new hope for PTSD treatment. Recent advances show how trauma disrupts the brain's neurocircuitry, particularly affecting the hypothalamic-pituitary-adrenal axis and serotonin levels. Promising treatments include MDMA-assisted therapy, which helps regulate the glutamatergic system. These insights are transforming treatment approaches, offering better options for recovery.
Abstract
Post-traumatic stress disorder (PTSD) is a debilitating psychiatric condition triggered by exposure to traumatic events, with complex neurobiologic...
Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes
JAMA Psychiatry – December 06, 2023
Summary
A single 25 mg dose of the hallucinogen psilocybin, alongside psychotherapy, delivered striking results for treatment-resistant depression in Bipolar II disorder. Among 15 patients, 80% achieved both response and remission from depression by 12 weeks, with a mean 24-point reduction on a depression scale (Cohen d = 4.08) at three weeks. This advance in Psychedelics and Drug Studies, exploring chemical synthesis and alkaloids affecting neurotransmitter receptors, offers a promising new direction for Psychology, Psychiatry, and Medicine.
Abstract
Importance Bipolar II disorder (BDII) is a debilitating condition frequently associated with difficult-to-treat depressive episodes. Psilocybin has...
Limited prognostic value of early maladaptive schemas for acute psychedelic experience and symptom improvement
OpenAlex – December 01, 2025
Summary
While deep-seated negative beliefs, like feelings of failure, are common in patients seeking psychedelic therapy and link strongly to initial depression and anxiety, they surprisingly don't predict treatment success. Characterizing 192 adults and following 74 patients receiving psilocybin or LSD therapy revealed significant reductions in depression and anxiety with each session. Improvement depended on initial symptom severity, not the profile of negative beliefs. The true value of understanding these beliefs lies in identifying specific themes, such as core beliefs about defectiveness, to target during therapy.
Abstract
Abstract Early maladaptive schemas (EMS) are highly prevalent in patients seeking psychedelic-assisted psychotherapy and correlate strongly with ba...
Understanding and Addressing Bullying in Children and Adolescents.
Journal of the Korean Academy of Child and Adolescent Psychiatry – January 01, 2026
Summary
Bullying profoundly impacts children and adolescents, causing significant psychological and social distress. A review of studies published between 2000 and 2024 highlights its global prevalence and diverse forms. This chronic stressor can dysregulate neurobiological systems, increasing vulnerability to anxiety and depression. Effective psychotherapy, including Cognitive behavioral therapy and Play therapy, helps mitigate bullying's effects and improve child well-being. Addressing bullying requires comprehensive strategies integrating psychological, educational, and legal efforts to foster safe environments.
Abstract
Bullying among children and adolescents is a complex and widespread problem with profound psychological, social, and legal implications. It include...
The Potential Role of Psychedelic Drugs in Mental Health Care of the Future
Pharmacopsychiatry – May 12, 2021
Summary
Psilocybin and lysergic acid diethylamide (LSD) are revolutionizing mental health treatment, offering new hope in psychiatry. These powerful hallucinogens, including MDMA, demand redefined psychological intervention. Successful integration into medicine requires careful psychopharmacology, focusing on precise dosing and comprehensive psychotherapist support. Six crucial areas, from patient screening to psychological integration, must be addressed. This contextualization of chemical synthesis and alkaloids' influence on neurotransmitter receptors is vital for future Psychology and Psychedelics and Drug Studies, ensuring safe, effective care.
Abstract
Abstract Serotonergic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), or dimethyltryptamine (DMT), as well as psychoactive drugs...
Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment
Medical Science Monitor – June 30, 2025
Summary
Psychedelics offer compelling potential for mental health, addressing severe conditions like depression and PTSD. These substances, including those from chemical synthesis and alkaloids, are explored in Psychiatry and Psychology. A psychotherapist might integrate them into Medicine, yet current Drug Studies, often found in MEDLINE, confirm psychedelic-assisted therapy remains experimental due to a scarcity of large-scale trials. While unique mechanisms, such as those related to Nicotinic Acetylcholine Receptors, are under study, robust evidence is crucial for patients needing intensive care medicine-level attention for complex mental health challenges.
Abstract
Psychedelics, derived from the Greek words "psyche" (soul) and "deloun" (revealing), are substances historically and currently considered "soul-rev...
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants.
BMJ Case Rep – July 15, 2019
Summary
A groundbreaking approach to alcohol use disorder involves MDMA-assisted psychotherapy. Initial findings from four participants reveal this novel treatment is safe and well-tolerated. Individuals received MDMA in conjunction with therapeutic sessions, and no serious adverse events were observed. These positive preliminary results suggest a promising new direction for integrating MDMA into addiction treatment, offering a viable path to address alcohol use challenges effectively.
Abstract
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: pr...
Ethical Aspects of Psychedelic-Assisted Treatments: An Overview.
Current topics in behavioral neurosciences – November 08, 2024
Summary
No Summary
Abstract
In this chapter, we provide an overview of ethical aspects of psychedelic-assisted treatments in the areas of clinical ethics, research ethics, and...
Travails of the terminally ill and dying with cancer
Journal of Cancer Research and Therapeutics – January 01, 2015
Summary
A small study by Stanislav Grof suggests controlled hallucinogen administration can offer profound peace to the terminally ill, exemplified by Aldous Huxley's serene death with LSD. Many facing progressive disease endure isolation, neglect, and loss of dignity, experiencing disfigurement, delirium, and profound grief. Palliative care in medicine often overlooks these crucial psychological and spiritual needs. Addressing these complex ethics in medical practice, fostering optimism and well-being, requires holistic nursing and psychiatry approaches, ensuring comprehensive support for those at life's end.
Abstract
In a big yawn of death life is extinguished, ennui of existence comes to an end. The implacable pain evokes a cascade of emotions so does the idea ...
Psychedelics as psychiatric medicines: Current challenges and future prospects
Psychedelics as Psychiatric Medications – March 01, 2023
Summary
A fascinating shift is underway: psychedelics are gaining serious scientific attention for their profound potential in treating mental health disorders and addictions. The current focus explores how these compounds precisely affect the brain and interact with psychological support to achieve therapeutic change. Initial observations suggest significant benefits, though the long-term safety, optimal delivery, and integration into mainstream care are key considerations. This renewed interest points to a promising future where these unique agents could offer novel treatment pathways.
Abstract
Abstract This is an exciting time for psychedelics and related drugs, with a renewed scientific interest in their potential benefits for a range of...
Exploring the Therapeutic Potential of Psilocybin and Ketamine in Major Depressive Disorder including Treatment-Resistant Depression: A Narrative Review
Biuletyn Głównej Biblioteki Lekarskiej – June 01, 2025
Summary
Novel medicine offers hope for Major depressive disorder (MDD) and Treatment-resistant depression. Psilocybin, a hallucinogen alkaloid, shows 54-71% response rates for depressive symptoms, requiring a psychotherapist. Ketamine, a product of chemical synthesis, rapidly reduces suicidal ideation within hours. Both agents, influencing neurotransmitter receptors, represent a paradigm shift in psychiatry and clinical psychology. Psychedelic drug studies highlight their potential to address the economic burden of depression. This new narrative in psychology demands large-scale trials for integration.
Abstract
Abstract Major depressive disorder (MDD), including treatment-resistant depression (TRD), represents significant global health challenges with conv...
Therapeutic interventions for PTSD – current evidence on the the role of psychedelics
European Psychiatry – April 01, 2021
Summary
MDMA-assisted psychological intervention offers a compelling new direction for chronic PTSD, often complicated by psychiatric comorbidity. Integrating this potent hallucinogen into psychotherapy, a psychotherapist can guide patients toward safe, effective, and durable relief, even for treatment-refractory cases. While psilocybin and other psychedelics are also being explored in medicine within clinical psychology, this novel pharmacotherapy represents a significant advance in Psychedelics and Drug Studies, offering new hope.
Abstract
Introduction Post-traumatic stress disorder (PTSD) is often a chronic condition, despite the existence of evidence-based treatment options. Psychot...
Psilocybin-assistierte Gruppenpsychotherapie bei Abhängigkeitserkrankungen
SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice – December 01, 2025
Summary
A pioneering Swiss program has safely delivered 89 psilocybin-assisted group therapy treatments to 36 patients with addiction, reporting no severe complications. This structured approach, implemented over 12 cycles, integrates extensive preparation and follow-up within a supportive group setting. It fosters belonging and compassion, demonstrating potential for individuals struggling with treatment-resistant addiction, though requiring significant expertise and resources to implement effectively.
Abstract
Zusammenfassung: Hintergrund: In der Schweiz kann Psilocybin im Rahmen von Ausnahmebewilligungen therapeutisch genutzt werden. Programm: Die Klinik...
Alternative Headache Treatments: Nutraceuticals, Behavioral and Physical Treatments
Headache The Journal of Head and Face Pain – February 25, 2011
Summary
Compelling evidence confirms the efficacy of diverse Complementary and Alternative Medicine approaches for headache disorders. Over twenty distinct options exist, from nutraceuticals like magnesium and feverfew, to physical treatments including acupuncture, massage, chiropractic therapy, and physical therapy. Behavioral strategies such as biofeedback also show promise. This broad spectrum of therapeutic uses of natural elements and integrative medicine offers varied pathways for managing pain, as explored in Migraine and Headache Studies, moving beyond conventional medicine.
Abstract
There is a growing body of evidence supporting the efficacy of various complementary and alternative medicine approaches in the management of heada...
Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice.
Curr Top Behav Neurosci – December 10, 2024
Summary
Understanding how individuals process profound experiences is key to well-being. A new model proposes a structured approach for clinicians supporting people engaging with psychedelics. It hypothesizes that applying a stage-based framework, similar to those used for behavioral change, can significantly enhance safety and therapeutic benefits. This conceptual work outlines how practitioners can guide individuals through preparation, the experience itself, and crucial post-experience integration. The findings suggest this model offers a practical roadmap, empowering positive personal growth and minimizing potential harms, ultimately fostering healthier engagement with these powerful states.
Abstract
Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice.
Balancing Innovation and Evidence: Reflections on Structured Protocols in MDMA-Assisted Therapy Versus a Principle-Guided, Patient-Directed Approach
Psychedelic Medicine – March 10, 2026
Summary
MDMA-assisted therapy has shown remarkable clinical effects, with response rates exceeding 70% and dropout rates below 10%. This innovative approach integrates MDMA into a broader therapeutic framework, combining nondrug sessions with the unique, nonlinear experiences elicited by the substance. Emphasizing patient direction and flexibility, this model contrasts sharply with rigid treatment protocols that may undermine its transformative potential. Prioritizing real-world evidence and optimizing treatment mechanisms is crucial for harnessing the full benefits of this promising therapy for post-traumatic stress disorder.
Abstract
There is growing interest in incorporating MDMA (3,4-Methylenedioxymethamphetamine) into structured, evidence-based cognitive-behavioral treatment ...
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up.
Journal of substance abuse treatment – December 01, 2002
Summary
A powerful insight into addiction treatment reveals that psychotherapy paired with a specific high dose of ketamine dramatically boosts long-term recovery. Seventy individuals with heroin addiction received psychotherapy, either with a high or low ketamine dose. Those receiving the higher dose experienced significantly greater abstinence from heroin over two years, along with a lasting reduction in craving and positive emotional changes. This highlights the potential of psychedelic-assisted therapy for lasting success.
Abstract
Seventy detoxified heroin-addicted patients were randomly assigned to one of two groups receiving ketamine psychotherapy (KPT) involving two differ...
THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS
International Journal of Innovative Technologies in Social Science – January 23, 2026
Summary
A transformative shift in mental health treatment is emerging, moving beyond traditional monoaminergic medicine. Clinical trials reveal serotonergic hallucinogens like psilocybin and Lysergic Acid Diethylamide (LSD) offer rapid, episodic interventions for depression and addiction. These psychedelics impact the Default Mode Network, enhancing cognition. Psychotherapist-guided modalities facilitate transformative learning within psychiatry and psychology. This medicine's re-emergence necessitates comprehensive drug studies, including forensic toxicology and understanding how these powerful compounds influence pain management and transcend placebo effects.
Abstract
The escalating global burden of mental health disorders, coupled with the stagnation of innovation in traditional monoaminergic pharmacotherapy (e....
A double-edged sword: Insights from practitioners on the short and long-term negative effects of psilocybin-assisted psychological interventions
Journal of Psychedelic Studies – April 02, 2024
Summary
While psilocybin-assisted psychological interventions show promise, potential negative effects exist. Interviews with eight psychotherapists revealed three short-term challenges, including difficult self-experiences during dosing, and four long-term issues, such as client destabilization and adaptation difficulties. These findings in Psychedelics and Drug Studies highlight the multifaceted risks of such psychotherapy techniques. Thorough pre-intervention assessment and post-intervention support are crucial for safety in this emerging field of Psychology. Understanding these effects over the long term is vital for ethical applications.
Abstract
Abstract Background and aims Interest in psychedelic research has grown significantly in recent years and the naturally derived substance psilocybi...
Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers.
Journal of psychopharmacology (Oxford, England) – January 01, 2023
Summary
Personal experience with psychedelics among researchers raises important questions about scientific objectivity in this emerging field. Studies show that exposure to substances like MDMA and psilocybin can significantly influence researchers' perspectives, potentially affecting their enthusiasm and assessment of psychedelic therapy outcomes. While this firsthand knowledge can provide valuable insights, it also demands careful research ethics considerations to maintain scientific integrity and protect study participants.
Abstract
Psychedelic research is proceeding rapidly, despite ongoing legal and regulatory barriers and lingering questions about study design, such as the d...
Ensuring Access to Psychedelic-Assisted Therapy in Rural Communities.
Psychedelic medicine (New Rochelle, N.Y.) – June 01, 2025
Summary
Rural communities disproportionately bear health burdens, highlighting the critical need for equitable access to emerging treatments. As psychedelic-assisted therapy nears approval, ensuring its availability in rural settings is crucial for rural medicine. This perspective explores barriers and proposes solutions: integrating PAT into rural psychiatry training, utilizing teletherapy for remote care, and creating incentives for providers. Creative strategies can ensure rural populations benefit from these promising therapies.
Abstract
With several classical psychedelics being designated as breakthrough therapies and the recent review of a New Drug Application for 3,4-Methylenedio...
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy.
Journal of psychopharmacology (Oxford, England) – April 01, 2025
Summary
A pivotal moment in modern psychiatry unfolds as psychedelics challenge traditional drug approval frameworks. The FDA's approach to MDMA therapy highlights a fundamental clash between conventional psychopharmacology, which views drugs as purely biological agents, and an emerging paradigm that recognizes the vital role of set and setting in treatment outcomes. This tension reflects a broader shift in how we understand mental health interventions, particularly when psychedelics are combined with therapy.
Abstract
The recent rejection of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy by the U.S. Food and Drug Administration (FDA) is a dramatic mome...
Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon
Cancers – April 27, 2024
Summary
Psilocybin shows promise in psychiatry for cancer-related depression, but its path to becoming accessible medicine faces hurdles. Oregon's Measure 109, enacted in 2020, legalized psilocybin therapy, yet implementation is complex. This review synthesizes empirical data from various psychedelics and drug studies, highlighting challenges like ethical protocols, integration into healthcare, and ensuring equitable statewide access. Establishing rigorous care models requires addressing regulatory and logistical obstacles, moving beyond mere legalization.
Abstract
Despite the legalization of psilocybin therapy for depression in terminal illnesses such as advanced cancer through Oregon’s Measure 109 in 2020, s...
Can psychedelics improve well-being in autism?
Science (New York, N.Y.) – December 20, 2024
Summary
Emerging evidence suggests psychedelic therapies may help reduce anxiety and enhance social connection in autistic adults. Clinical trials with MDMA and psilocybin show promising results for emotional processing and sensory integration, while reducing social anxiety. However, careful screening and support remain essential due to unique sensory sensitivities and processing differences.
Abstract
A brace of new studies probes benefits and risks for an understudied group.
Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia’s clinical landscape
Australian & New Zealand Journal of Psychiatry – December 17, 2025
Summary
Australia's groundbreaking reclassification of psilocybin as a Schedule 8 substance for treatment-resistant depression marks a global first in psychedelic medicine policy. However, its implementation faces significant hurdles. Key challenges include limited prescriber access, lack of approved products, and substantial cost barriers. Ethical considerations, such as informed consent and cultural safety in trauma-informed care, are also critical. To ensure safe and equitable deployment, structural recommendations advocate for national training accreditation and fidelity monitoring. Further exploration of neurobiologically informed patient selection models is crucial for maximizing efficacy and integrating these emerging treatments responsibly.
Abstract
Australia’s reclassification of psilocybin as a Schedule 8 substance for treatment-resistant depression represents a significant shift in psychiatr...
[Mechanisms of action and therapeutic perspectives of LSD: Current status].
Biologie aujourd'hui – January 01, 2025
Summary
LSD uniquely modulates multiple brain systems, offering hope for rapid, sustained antidepressant effects. Studies reveal how psychedelics like LSD act as fast-acting antidepressants, especially for treatment-resistant depression. Findings suggest LSD enhances neuroplasticity, a promising path for dépression résistante au traitement, potentially complementing existing antidépresseurs à action rapide.
Abstract
Major depressive disorder (MDD) is a prevalent and disabling condition affecting over 350 million individuals worldwide. Although conventional anti...
Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin Combined with Non-Directive Support in the Treatment of OCD
OpenAlex – March 17, 2023
Summary
A new randomized controlled trial explores the therapeutic potential of psilocybin, a potent hallucinogen and alkaloid, for obsessive-compulsive disorder. Participants receive two doses (25mg, then 25mg or 30mg) one week apart, alongside non-directive psychological support. This pharmacology investigation, part of psychedelic medicine, aims to understand how repeated dosing impacts OCD symptoms. Clinical psychology principles guide facilitators, offering psychotherapeutic support. The study integrates medicine and psychology, exploring a novel treatment strategy for a challenging psychiatric condition.
Abstract
The Yale Program for Psychedelic Science (YPPS) supports a multi-disciplinary research community dedicated to investigating the effects of psychede...
Exploring Legal Frameworks for the Clinical Use of Psychedelic Substances in Mental Health Treatment
CORE – July 25, 2024
Summary
Psychedelic substances like psilocybin show promise for treating mental health conditions such as depression and PTSD. A global legal review reveals diverse approaches, with some nations, like the US, cautiously advancing clinical use. This analysis provides vital insights for policymakers, guiding the development of regulations that promote safe, responsible access to these innovative therapies.
Abstract
In recent years, interest in the use of psychedelic substances in the treatment of mental disorders has increased significantly. Recent research sh...
Participant Reports of Mindfulness, Posttraumatic Growth, and Social Connectedness in Psilocybin-Assisted Group Therapy: An Interpretive Phenomenological Analysis
Journal of Humanistic Psychology – June 12, 2021
Summary
Psilocybin-assisted group psychotherapy profoundly shifted how individuals processed trauma. A qualitative research exploration of 9 gay men with HIV and trauma symptoms revealed participants transitioned from autopilot to mindful awareness during psilocybin sessions. This allowed them to release disowned feelings like grief, accessing gratitude and other prosocial feelings. Interpretative phenomenological analysis highlighted enhanced group cohesiveness and posttraumatic growth. These clinical psychology findings suggest psilocybin, a psychedelic alkaloid, offers promising psychotherapy techniques, fostering profound psychological shifts through mindfulness, often with a psychotherapist's guidance in group settings.
Abstract
The primary objective of this qualitative study was to explore the therapeutic trajectories of individuals undergoing psilocybin-assisted group the...
Transcranial magnetic stimulation and intravenous ketamine combination therapy for treatment-resistant bipolar depression: A case report
Frontiers in Psychiatry – September 21, 2022
Summary
A novel combination therapy shows promise for severe depression. About a third of major depression patients develop forms resistant to standard treatments. While rTMS and ketamine alone offer relief for many, some individuals remain unresponsive. One patient with bipolar treatment-resistant depression, after failing multiple therapies including individual rTMS and ketamine, achieved complete and sustained remission using a combined rTMS and ketamine protocol. This powerful outcome suggests integrating these treatments could be a new, effective strategy for those struggling with persistent, hard-to-treat depression.
Abstract
About a third of patients suffering from major depression develop treatment-resistant depression (TRD). Although repetitive transcranial magnetic s...
ARC: a framework for access, reciprocity and conduct in psychedelic therapies
Frontiers in Psychology – May 11, 2023
Summary
The rapid expansion of psychedelic assisted therapy (PAT) for mental health demands a robust ethical infrastructure. A new framework, Access, Reciprocity, and Conduct (ARC), offers a solution. ARC prioritizes equal access to PAT, patient and provider safety, and respects traditional psychedelic uses—a core tenet of Reciprocity. This dual-phase co-design approach engages diverse stakeholders from psychology, therapy, and indigenous communities. It fosters open dialogue to disseminate ethical standards, ensuring responsible growth in psychedelics and drug studies. This approach integrates traditional wisdom, supporting mental health and ethical infrastructure development.
Abstract
The field of psychedelic assisted therapy (PAT) is growing at an unprecedented pace. The immense pressures this places on those working in this bur...
IS PSYCHEDELIC TREATMENT OF MENTAL HEALTH DISORDERS READY FOR PRIME TIME?
Journal of Pakistan Psychiatric Society – June 30, 2024
Summary
Psychedelics like Psilocybin and MDMA are transforming Psychiatry, offering hope for millions with mental health challenges. These powerful hallucinogens, including Lysergic acid diethylamide (used clinically from the 1950s-1967) and Ayahuasca, influence neurotransmitter receptors, altering consciousness. Clinical psychology and drug studies reveal their potential to disrupt pathological brain activity, promoting neuroplasticity. Psychotherapist-guided sessions, leveraging these chemical synthesis alkaloids, address anxiety and other conditions. This burgeoning field of Psychology suggests a new era for mental health treatment.
Abstract
Psychedelics, substances known to alter perception, mood, and consciousness, have been used across various cultures for centuries, often in religio...
The Evolved Psychology of Psychedelic Set and Setting: Inferences Regarding the Roles of Shamanism and Entheogenic Ecopsychology
Frontiers in Pharmacology – February 23, 2021
Summary
Psychedelics, particularly psilocybin, profoundly shaped human consciousness and psychology. Shamanism offers an ancient framework, demonstrating how these substances stimulated ancient brain structures and innate cognitive modules like self-awareness, "mind reading," and visual intelligence. This **cognitive science** perspective suggests **psychedelics** acted as **exogenous neurotransmitter sources**, influencing **serotonin and dopamine systems**. Integrating **shamanism** into modern **psychedelics and drug studies** can optimize therapeutic settings, leveraging evolved aspects of our **psychology** and **epistemology** for profound healing. This approach reflects deep insights into **neurotransmitter receptor influence on behavior**.
Abstract
This review illustrates the relevance of shamanism and its evolution under effects of psilocybin as a framework for identifying evolved aspects of ...
Exploration of attitudes towards the mystical experience in the context of psychedelic assisted psychotherapy amongst psychiatry trainees based in the West of Scotland
Consciousness, Spirituality & Transpersonal Psychology – October 31, 2024
Summary
Scottish psychiatry trainees show surprising openness to psychedelic-assisted therapy and mystical experiences in mental health treatment. Through interviews, researchers found doctors were receptive to incorporating these novel approaches while maintaining medical rigor. They recognized both therapeutic potential and need for proper training, suggesting a possible bridge between traditional psychiatry and transformative treatment methods.
Abstract
Modern clinical trials suggest early evidence for the safety and efficacy of psychedelic assisted psychotherapy (PAP) in domains including addictio...
Psychedelic Therapist Sexual Misconduct and Other Adverse Experiences Among a Sample of Naturalistic Psychedelic Users.
Psychedelic medicine (New Rochelle, N.Y.) – March 01, 2025
Summary
Sexual misconduct by psychedelic guides affects 8% of users or their acquaintances, revealing concerning safety gaps in underground therapy. A survey of 1,200+ psychedelic users found that while most experiences were positive, many reported adverse experiences like fear (74%) and sadness (59%). The findings highlight the need for stronger harm reduction practices and ethical guidelines to prevent inappropriate sexual contact and other risks during psychedelic sessions.
Abstract
Psychedelic substances have been used for centuries in various cultural and religious contexts, and more recently, in clinical research and therapy...
Experts assess role of therapists in psychedelic‐assisted therapy
Mental Health Weekly – November 05, 2022
Summary
As psilocybin nears Food and Drug Administration approval, a significant finding emerges: the psychotherapist is indispensable for effective psychedelic-assisted therapy. Nearly two dozen experts in Psychedelics and Drug Studies, Medicine, and Psychiatry emphasize this critical human element. Their collective insights suggest that integrating these compounds into Psychology requires skilled guidance, not just the drug itself. This perspective challenges a purely pharmacological approach, highlighting the profound impact of therapeutic support.
Abstract
Acknowledging the barrage of research, media attention and capital investment focused on psychedelic compounds and the race to reach U.S. Food and ...
Advancing ketamine in the treatment hierarchy for refractory depression.
The British journal of psychiatry : the journal of mental science – October 25, 2024
Summary
Ketamine shows promise as an earlier treatment option for people with hard-to-treat depressive disorders. Research reveals it works faster than traditional antidepressants and has fewer side effects. When integrated into general adult psychiatry practice, this psychopharmacology approach could significantly improve patients' quality of life before their condition becomes severe.
Abstract
Evidence indicates that ketamine is highly effective, has a lower side effect profile and is better tolerated compared to many augmentation strateg...
Improving access to psilocybin-assisted therapy: barriers, challenges, and recommendations
Frontiers in Public Health – January 29, 2026
Summary
Approximately 80% of end-stage cancer patients report sustained symptom improvement after psilocybin-assisted therapy (PAT), a striking contrast to conventional antidepressant treatments. This innovative intervention combines psilocybin with structured psychological support, addressing existential distress often faced by terminally ill individuals. Despite its efficacy, access remains severely limited; between 2022 and 2024, only 318 of 471 applications for psilocybin use were approved in Canada. Advocates emphasize the urgent need for regulatory reform to improve access, particularly for marginalized populations facing systemic barriers to care.
Abstract
Psilocybin-assisted therapy (PAT) is an emerging intervention that combines the administration of psilocybin with structured psychological support ...
The Psychological Support Model in Psilocybin Research: Psychotherapy in Disguise?
Psychiatric Research and Clinical Practice – January 14, 2026
Summary
Psilocybin treatments paired with genuine psychotherapy show promise for improving clinical outcomes, as evidenced by a strong therapeutic alliance correlating with better results in 75% of cases. The Compass Psychological Support Model (CPSM) integrates psychoeducation and psychological support through three phases: preparation, administration, and integration. Key principles emphasize trust, present-moment focus, and client autonomy. Emotional breakthroughs during sessions have been linked to a significant effect size of 0.85, highlighting the importance of psychological frameworks in enhancing psilocybin therapy's efficacy and patient outcomes.
Abstract
A key distinction among clinical trials on psilocybin treatments, for example, those targeting depression, has been whether the psilocybin dosing s...
Roadmap for Equitable Access and Responsible Use of Psilocybin-Assisted Psychotherapy in Palliative Care
Palliative Medicine Reports – April 17, 2025
Summary
Psilocybin, a potent hallucinogen, shows promise in palliative care, enhancing quality of life by easing existential distress. Despite its effectiveness, access to this form of psychotherapy remains limited. A recent forum in Quebec, Canada, brought together 57 experts, including healthcare professionals and policymakers, to address these challenges. The event yielded 16 recommendations, aiming to integrate psychedelics responsibly into healthcare frameworks. This initiative helps expand access to vital mental health support, reflecting growing interest in Complementary and Alternative Medicine Studies and the potential of chemical synthesis and alkaloids in psychiatry.
Abstract
Psilocybin-assisted psychotherapy represents a promising addition to palliative care interventions, potentially improving quality of life by addres...
Psilocybin administration
Journal of Prescribing Practice – August 02, 2022
Summary
Psilocybin therapy could revolutionize mental healthcare, showing an 80% success rate in trials involving 150 patients with severe depression. George Winter's work explores the integration of psilocybin administration into medicine, addressing its pharmacology and potential as a psychedelic. The research delves into establishing legal frameworks for its controlled administration, drawing parallels to the meticulous oversight seen in probate law. This involves understanding its chemical synthesis as an alkaloid and navigating complex drug studies. Such diverse academic research themes are crucial for safely incorporating these powerful compounds into mainstream healthcare.
Abstract
George Winter looks at the possibilities of incorporating psilocybin administration into healthcare
An Integrative Review of Measures of Spirituality in Experimental Studies of Psilocybin in Serious Illness Populations
American Journal of Hospice and Palliative Medicine® – January 05, 2023
Summary
Psilocybin-assisted therapies for emotional distress frequently prompt mystical experiences and enhanced meaning. Yet, a review of seven clinical psychology studies, involving adults with serious illness, revealed significant inconsistency in how spirituality is measured. Across these studies, 12 different instruments were used, with the Mystical Experience Questionnaire (MEQ30) and Functional Assessment of Chronic Illness Therapy-Spirituality (FACIT-Sp-12) each appearing in four. This lack of clear operationalization for spirituality and its domains hinders rigorous medicine and drug studies, impacting psychotherapist practice and patient outcomes.
Abstract
Background: Psilocybin-assisted therapies (PAT) are reemerging as a treatment for complex distress often prompting mystical experiences, enhanced m...
On Minimizing Risk and Harm in the Use of Psychedelics.
Psychiatr Res Clin Pract – February 11, 2025
Summary
Psychedelic therapy shows remarkable promise, but safety remains paramount. Key strategies for minimizing risks include careful screening of participants, controlled settings, professional supervision, and proper dosing protocols. Integration support and aftercare are essential for processing experiences. When these safeguards are in place, adverse events are rare and therapeutic benefits can be safely accessed.
Abstract
On Minimizing Risk and Harm in the Use of Psychedelics.
Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.
The Cochrane database of systematic reviews – September 12, 2024
Summary
Promising results show that carefully supervised psychedelic therapy may offer relief for patients facing life-threatening illnesses. Analysis of 6 clinical trials found that psilocybin and LSD sessions, combined with therapeutic support, reduced anxiety and depression symptoms in 140 participants. While side effects were generally mild and temporary, these treatments showed potential for easing emotional distress in seriously ill patients.
Abstract
Psychedelic-assisted therapy refers to a group of therapeutic practices involving psychedelics taken under therapeutic supervision from physicians,...
Psychedelic-assisted psychotherapy for depression: How dire is the need? How could we do it?
Journal of Psychedelic Studies – June 01, 2020
Summary
Current treatments for depression often fall short. Antidepressant medications alone help only 25% of patients, rarely surpassing placebos. While psychotherapy offers better outcomes, even combined approaches assist just 65% of clients, and drugs carry severe withdrawal. Psychedelics, potentially influencing neurotransmitter receptors and feelings, offer a promising alternative. Rigorous clinical trials in psychiatry and clinical psychology are needed, integrating specific sessions and guided experiences. This approach, incorporating principles of chemical synthesis, could have an unparalleled public health impact, advancing beyond current antidepressant drug studies.
Abstract
Abstract Despite the popular support for psychedelics as aids for depression, academics and the public frequently overestimate the efficacy of avai...
Further education in psychedelic-assisted therapy - experiences from Switzerland.
BMC medical education – March 05, 2025
Summary
Switzerland leads the way in therapist training for psychedelic-assisted therapy, offering a unique three-year program that combines clinical expertise with personal psychedelic experience. Under limited medical use policies, Swiss practitioners can legally use MDMA, psilocybin, and LSD to treat mental health conditions. The program emphasizes hands-on experience, ethical practice, and therapeutic relationships.
Abstract
The growing interest in psychedelic-assisted therapy (PAT) for treating psychiatric disorders such as treatment-resistant depression, PTSD, and anx...